The investment bank based the upgrade on potential for growth in the installed base of Quidel's immunoassay and molecular instruments, among other factors.
The investment bank said that it thinks 2018 will be a good year for clinical sequencing and that overall demand for high-throughput sequencing remains high.
The investment bank's upgrade is based on an expectation of resilient revenue growth for the firm's molecular diagnostics business, among other growth drivers.
Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.
Canaccord and William Blair also increased their price targets on Quidel's shares, following its acquisition of certain Alere assets and assays.
Analyst Nicholas Jansen set a price target at $116, pointing to expanding professional lab services, consumer-focused programs, and M&A as growth drivers.
Janney analyst Paul Knight cited a rebound in the company's shares that is due to an expected easy sequential earnings comparison for Q1, among other reasons.
The investment bank Evercore ISI upgraded Illumina's stock in anticipation of sales of its NovaSeq sequencing instrument.
The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.
The investment bank noted Veracyte's "disciplined" approach to developing and commercializing tests, and said the company stands out in its sector.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.